Freja Albjerg Venning

Freja Albjerg Venning

Auto-generated profile, based on publicly available information

Freja Albjerg Venning

University of Copenhagen

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
FVFreja A. Venning
Freja A. Venning
LWLena Wullkopf
Lena Wullkopf
JEJanine Terra Erler
Janine Terra Erler
Metastatic complications are responsible for more than 90% of cancer related deaths. The progression from an isolated tumor to disseminated metastatic disease is a multi-step process, with each step involving intricate cross-talk between the cancer cells and their non-cellular surroundings, the extracellular matrix (ECM). Many ECM proteins are significantly de-regulated during the progression of cancer, causing both biochemical and biomechanical changes that together promote the metastatic cascade. In this review, the influence of several ECM proteins on these multiple steps of cancer spread is summarized. In addition, we highlight the promising (pre-)clinical data showing benefits of targeting these ECM macromolecules to prevent cancer progression.

12 June 2017 in Nature Medicine
Verified
Journal Article
Closed access
AMAlejandro E Mayorca-Guiliani
Alejandro E Mayorca-Guiliani
CMChris D Madsen
Chris D Madsen
TCThomas R. Cox
Thomas R. Cox
EHEdward R Horton
Edward R Horton
FVFreja A Venning
Freja A Venning
JEJanine Terra Erler
Janine Terra Erler

31 August 2015 in EMBO Reports
Verified
Journal Article
Open access
PDF file
CMChris D Madsen
Chris D Madsen
JPJesper T Pedersen
Jesper T Pedersen
FVFreja A Venning
Freja A Venning
LSLukram Babloo Singh
Lukram Babloo Singh
Emad MoeendarbaryEmad Moeendarbary
Emad Moeendarbary
JEJanine Terra Erler
Janine Terra Erler
Cancer‐associated fibroblasts (CAFs) interact with tumour cells and promote growth and metastasis. Here, we show that CAF activation is reversible: chronic hypoxia deactivates CAFs, resulting in the loss of contractile force, reduced remodelling of the surrounding extracellular matrix and, ultimately, impaired CAF‐mediated cancer cell invasion. Hypoxia inhibits prolyl hydroxylase domain protein 2 (PHD2), leading to hypoxia‐inducible factor (HIF)‐1α stabilisation, reduced expression of αSMA and periostin, and reduced myosin II activity. Loss of PHD2 in CAFs phenocopies the effects of hypoxia, which can be prevented by simultaneous depletion of HIF‐1α. Treatment with the PHD inhibitor DMOG in an orthotopic breast cancer model significantly decreases spontaneous metastases to the lungs and liver, associated with decreased tumour stiffness and fibroblast activation. PHD2 depletion in CAFs co‐injected with tumour cells similarly prevents CAF‐induced metastasis to lungs and liver. Our data argue that reversion of CAFs towards a less active state is possible and could have important clinical implications.

5 December 2013 in APMIS
Verified
Journal Article
Closed access
PDF file
FVFreja Albjerg Venning
Freja Albjerg Venning
MTMette Louise Trempenau
Mette Louise Trempenau
ESEsben Schmidt
Esben Schmidt
MCMogens Helweg Claesson
Mogens Helweg Claesson

6 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FVFreja Albjerg Venning
Freja Albjerg Venning
KZKamilla Westarp Zornhagen
Kamilla Westarp Zornhagen
LWLena Wullkopf
Lena Wullkopf
MHMorteza Chalabi Hajakrim
Morteza Chalabi Hajakrim
KWKyoung Jae Won
Kyoung Jae Won
JEJanine Terra Erler
Janine Terra Erler
Cancer-associated fibroblasts (CAFs) comprise a heterogeneous population of stromal cells within the tumour microenvironment. CAFs exhibit both tumour-promoting and tumour-suppressing functions, making them exciting targets for improving cancer treatments. A careful identification and characterisation of the CAF heterogeneity is thus necessary before implementing CAF-targeted strategies in cancer. With that in mind, we developed a flow cytometry strategy based on exclusion of non-CAF cells and successfully employed it to explore the temporal heterogeneity of CAFs in two models of triple-negative breast cancer (4T1 and 4T07). Analysing 128 murine tumours we identified 5-6 main CAF subpopulations and numerous minor ones based on the analysis of alpha smooth muscle actin, fibroblast activation protein alpha, platelet derived growth factor receptor alpha and beta, CD26/DPP4 and podoplanin. All markers showed temporal changes, and CD26+ CAFs emerged as a large novel subpopulation. These results form the foundation needed for the future elucidation of tumour-promoting CAF subpopulations.